In conclusion, the present study showed that administration of SeP-neutralizing Ab could improve, at least in KKAy mice model, glucose metabolism, insulin resistance and insulin secretion in vivo, and suggested a strategy of targeting SeP for treatment of type 2 diabetes. The gene discussed is SELENOP; the disease is type 2 diabetes mellitus.